The purpose of this study was to evaluate the efficacy and safety of low power micro radiofrequency (RF) therapy (μRFthera®) through urethra in the treatment of overactive bladders (OAB) through a prospective, single-blind, placebo-controlled, multi-center clinical protocol.
One hundred and fourteen patients with refractory OAB were randomized at 2:1 ratio, treatment to control undergoing same procedures except only the micro-RF treatment group at turned "on" setting in energy. Bladder diaries recorded during the screening period (3 days before enrollment) and during follow-up period on week 1, 3, and 7, respectively. The patients in control could choose receiving an energized treatment during extension stage.
The treatment efficacy was 76.1%. There was 49.80% rate improvement compared to control (95%CL 32.48%, 67.13%). The crude rate ration (RR) was 2.89, 95% CI (1.67-5.01) with p < 0.001 in uni-variate analysis, while the RR became 2.94, 95% CI (1.67-5.16) with p < 0.001 after adjusted potential confounding factors in multi-variate analysis. Statistically significant improvements have been demonstrated in the frequency of urination, urgency, nocturia, and quality of life (QoL) scores.
Micro RF therapy is safe and effective for the treatment of OAB. The main treatment-related complications were catheterization related complications.
Zhejiang Device Registration Certificate No. 202090909, www.chictr.org.cn, Clinical Trial Accession Number: ChiCTR2100050096.
Frontiers in medicine. 2022 May 12*** epublish ***
Zhi-Hui Xu, Peng-Fei Zhang, Yu-Feng Wang, Ao Ma, Yasmeen Bano, Alisherjon Ibrohimov, Chen Zhang, Hao-Fei Jiang, Yang Zhang, Yan-Lan Yu, Hai-Hong Jiang
Zhejiang Provincial People's Hospital, Hangzhou, China., The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China., Zhejiang-California International NanoSystems Institute, Hangzhou, China., Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China.